Event Information

Time: February 6, 2014 (Thursday) 09:30-11:00

Place: Mainland Affairs Council
(15FL., No. 2-2, Sec 1, Jinan Rd., Taipei, Taiwan)

The representatives of pharmaceutical associations were accompanied by Dr Wu (Vice Director-General of the TFDA) and Dr Hsiao (adviser to the TFDA ) to visit the Mainland Affairs Council (MAC) and were received by Ms Wu Mei-Hung, Vice Chairperson of the MAC. The agenda of this visit was about the promotion of cross-strait healthcare cooperation.

Mr Wang, the Minister of the MAC, was soon to visit China to review the implementation of various cross-strait agreements. The TRPMA prepared a petition to the MAC. The petition included two issues: 1. A special project of piloting the cross-strait cooperation in new drug R&D should be set up by the MAC and the ARATS and be subject to regular review; 2. A fast-track assessment of drugs manufactured in Taiwan should be established. The TRPMA hoped the petition could help the MAC better understand the industrys positions and hence form consensuses.

Ms Wu Mei-Hung (Vice Chairperson of MAC), Dr Wu Shiou-Ing (Deputy Director-General of the TFDA) and Dr Hsiao Mei-Ling (Adviser to the TFDA)

Mr Wang Shun-Mu (President of TGPA), Mr Huang Po-Hsiung (President of Johnson & Johnson Taiwan), Mr Tsai Cheng-Hung (Standing Director of the TRPMA) and Ms Wu Mei-Hung (Vice Chairperson of the MAC)